2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types

Wenham, R., Ghamande, S., Makker, V., Hou, J., Duska, L., Matei, D., Bhave, M., Scott, R., Hawk, N., Song, T., & Armstrong, D. K. (2022). 2022-RA-1241-ESGO A multicentre, open-label phase 1/2 trial evaluating the safety, tolerability, and efficacy of morab-202, a folate receptor alpha-targeting antibody-drug conjugate in patients with selected tumour types. Ovarian Cancer, A312.3-A313. https://doi.org/10.1136/ijgc-2022-esgo.667
Authors:
Robert M. Wenham
Sharad Ghamande
Vicky Makker
June Y. Hou
Linda Duska
Daniela Matei
Manali Bhave
Rachael Scott
Natalyn Hawk
Tingting Song
Deborah K. Armstrong
Affiliated Authors:
June Y. Hou
Subjects:
HER2 Signaling in Breast Cancer Treatment (OpenAlex Topic)
Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1136/ijgc-2022-esgo.667
DOI:
10.1136/ijgc-2022-esgo.667
Journal:
International Journal of Gynecological Cancer
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record

Record Created: